Use of Pneumatic tube systems (PTS's) poses a risk to inherently unstable protein therapeutics. Mechanical stress caused by those systems can lead to aggregation, compromising product safety and quality. However, PTS's are widely used in hospitals, and contradictory effects on protein stability have been reported.
Methods
We studied whether mechanical stress levels differ between hospitals and routes, potentially leading to different findings regarding protein aggregation. By transporting a mechanical sensor on nine different PTS routes in seven different hospitals, we quantified the accelerations that protein therapeutics experience in a specific PTS setup.
Results
It was found that the maximum acceleration within the different PTS setups was similar. However, transportation times differed up to 4-fold, leading to varying amounts of cumulative stress.
Conclusion
The cumulative and maximum stress quantified can be compared to stress found in studies investigating protein stability, which justifies the usage of mechanical sensors for risk evaluation. The differences in stress found underscore the importance of evaluating handling practices individually in each hospital, for each therapeutic protein.
KieseSPapppenbergerAFriessW, et al.Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci2008; 97: 4347–4366.
2.
Le BasleYChennellPTokhadzeN, et al.Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci2020; 109: 169–190.
3.
MahlerHCFriessWGrauschopfU, et al.Protein aggregation: pathways, induction factors and analysis. J Pharm Sci2009; 98: 2909–2934.
4.
RippleDCDimitrovaMN. Protein particles: what we know and what we do not know. J Pharm Sci2012; 101: 3568–3579.
5.
WangWRobertsCJ. Protein aggregation - mechanisms, detection, and control. Int J Pharm2018; 550: 251–268.
6.
NejadnikMRRandolphTWVolkinDB, et al.Postproduction handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci2018; 107: 2013–2019.
7.
LuoSMcSweeneyKMWangT, et al.Defining the right diluent for intravenous infusion of therapeutic antibodies. MAbs2020; 12: 1685814.
8.
WozniewskiMBesheerAHuwylerJ, et al.A survey on handling and administration of therapeutic protein products in German and Swiss hospitals. J Pharm Sci2024; 113: 735–743.
9.
BeeJSSchwartzDKTrabelsiS, et al.Production of particles of therapeutic proteins at the air-water interface during compression/dilation cycles. Soft Matter2012; 8: 10329–10335.
10.
KotarekJStuartCDe PaoliSH, et al.Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events. J Pharm Sci2016; 105: 1023–1027.
11.
MoussaEMPanchalJPMoorthyBS, et al.Immunogenicity of therapeutic protein aggregates. J Pharm Sci2016; 105: 417–430.
12.
RatanjiKDDerrickJPDearmanRJ, et al.Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol2014; 11: 99–109.
13.
HeljoPAhmadiMSchackMMH, et al.Impact of stress on the immunogenic potential of Adalimumab. J Pharm Sci-Us2023; 112: 1000–1010.
14.
NarhiLOChouDKChristianTR, et al.Stress factors in primary packaging, transportation and handling of protein drug products and their impact on product quality. J Pharm Sci2022; 111: 887–902.
15.
NarhiLOCorvariVRippleDC, et al.Subvisible (2-100 mum) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy. J Pharm Sci2015; 104: 1899–1908.
16.
KjellstromACederwallIMartinezCS, et al.Pneumatic tube transport of trastuzumab in IV bags-effect of headspace and surfactant on subvisible particle formation. J Pharm Sci2025; 114: 1142–1151.
17.
LinkuvieneVRossELCrawfordL, et al.Effects of transportation of IV bags containing protein formulations via hospital pneumatic tube system: particle characterization by multiple methods. J Pharm Sci2022; 111: 1024–1039.
18.
BarreauPFeutryFAbeleM, et al.Transportation of protein drugs at hospital: comparison of mechanical stress occurring during pneumatic transportation and hand-carried transport. J Pharm Sci2025; 114: 103715.
19.
RandolphTWSchiltzESederstromD, et al.Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation. J Pharm Sci2015; 104: 602–611.
20.
WangPNguyenL. Update to delivering medications via a pneumatic tube system. Am J Health Syst Pharm2017; 74: 1521–1522.
21.
CohrsMClottensNRamautP, et al.Impact of pneumatic tube transportation on the aggregation of monoclonal antibodies in clinical practice. Eur J Pharm Sci2025; 204: 106952.
22.
ColiatPErbSDiemerH, et al.Influence of pneumatic transportation on the stability of monoclonal antibodies. Sci Rep2023; 13: 21875.
23.
DesaiKGColandeneJDCrottsG, et al.Transportation of mAb dosing solution in intravenous bag: impact of manual, vehicle, and pneumatic tube system transportation methods on product quality. Mol Pharm2023; 20: 6474–6491.
24.
HendrickxTDe GrooteCBalcaenK, et al.Effect of pneumatic tube transport on monoclonal antibody stability. Belgian Journal of Hospital Pharmacy2023; 1: 4.
25.
WiteofAEDanielsALReaLT, et al.Machine learning and accelerated stress approaches to differentiate potential causes of aggregation in polyclonal antibody formulations during shipping. J Pharm Sci2021; 110: 2743–2752.
26.
SiskaCHarberPKerwinBA. Shocking data on parcel shipments of protein solutions. J Pharm Sci2020; 109: 690–695.
27.
ZollsSTantipolphanRWiggenhornM, et al.Particles in therapeutic protein formulations, part 1: overview of analytical methods. J Pharm Sci2012; 101: 914–935.
28.
HongPKozaSBouvierES. Size-Exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol2012; 35: 2923–2950.
29.
CarpenterJFRandolphTWJiskootW, et al.Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci2009; 98: 1201–1205.
30.
ArvidssonJAlkhatibYEgenM, et al.Exploring industry stakeholder perspectives on a clinical testbed for evaluating the handling of protein drugs in hospitals. J Pharm Sci2025; 114: 103704.
31.
DesaiKGColandeneJDSofaC, et al.A Novel Laboratory-scale pneumatic tube system (PTS) transportation model to assess the impact of hospital PTS transportation on the product quality of therapeutic monoclonal antibodies. Mol Pharm2025. DOI: 10.1021/acs.molpharmaceut.5c00428
32.
Sabate-MartinezCPaulssonMGonzalez-SuarezS, et al.How are we handling protein drugs in hospitals? A human factors and systems engineering approach to compare two hospitals and suggest a best practice. Int J Qual Health Care2024; 36. DOI: 10.1093/intqhc/mzae020
